Merrimack Pharmaceuticals
MACK
#8845
Rank
A$0.32 B
Marketcap
A$22.11
Share price
0.00%
Change (1 day)
-1.99%
Change (1 year)

Earnings for Merrimack Pharmaceuticals (MACK)

Earnings in 2024 (TTM): -A$3.43 Million

According to Merrimack Pharmaceuticals's latest financial reports the company's current earnings are N/A. In 2023 the company made an earning of -A$3.18 Million a decrease over its 2022 earnings that were of -A$3.18 Million. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Merrimack Pharmaceuticals from 2010 to 2024

Annual earnings

Year Earnings Change
2024 (TTM) -A$3.43 Million7.65%
2023 -A$3.18 Million0.09%
2022 -A$3.18 Million-16.9%
2021 -A$3.83 Million-49.89%
2020 -A$7.63 Million-75.39%
2019 -A$31 Million-68.58%
2018 -A$98.65 Million-19.4%
2017 -A$0.13 Billion-36.46%
2016 -A$0.2 Billion2.54%
2015 -A$0.19 Billion96.78%
2014 -A$95.47 Million-45.44%
2013 -A$0.18 Billion
2010 -A$67.86 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Sanofi
SNY
A$11.38 B-344,855.64%๐Ÿ‡ซ๐Ÿ‡ท France
Geron
GERN
-A$27.82 Million 742.72%๐Ÿ‡บ๐Ÿ‡ธ USA
Clovis Oncology
CLVS
-A$0.32 Billion 9,523.90%๐Ÿ‡บ๐Ÿ‡ธ USA
AVEO Oncology
AVEO
-A$42.44 Million 1,185.48%๐Ÿ‡บ๐Ÿ‡ธ USA
Eterna Therapeutics
ERNA
-A$24.15 Million 631.30%๐Ÿ‡บ๐Ÿ‡ธ USA